RIPK1 and triple-A syndrome: Wang et al. went on to show that in the elastase perfusion mouse model of AAA, the RIPK1 inhibitor Necrostatin-1s (Nec-1s), an optimized form of Nec-1, can slow aneurysm growth after aneurysm formation.